Joint Bayesian Inference of Genetic Effect Sizes and PK Parameters in Nonlinear Mixed-Effects Models
Julien Martinelli, Ibtissem Rebai, David W. Haas, Julie Bertrand · 2026
Read Joint Bayesian Inference of Genetic Effect Sizes and PK Parameters in Nonlinear Mixed-Effects Models by Julien Martinelli, Ibtissem Rebai, David W. Haas, Julie Bertrand (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2604-14364.txt.
Introduction
Martinelli, Rebai, Haas, and Bertrand build a Bayesian framework jointly estimating population drug parameters and SNP effect sizes. Five sparsity-inducing priors compete in simulations, where false-discovery rates stay low with no effect and signals return with real effects, at peak F1 scores around 0.8 to 0.85. The spike-and-slab prior stands out by giving posterior inclusion probabilities, while the l1-ball prior pairs similar recovery with steadier behavior across tolerance settings. On 129 Cambodians with HIV on nevirapine, checks show good calibration and stable drug-model estimates across priors.
Catalog record
| CREATOR | Julien Martinelli, Ibtissem Rebai, David W. Haas, Julie Bertrand |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87180 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2604.14364
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Joint Bayesian Inference of Genetic Effect Sizes and PK Parameters in Nonlinear Mixed-Effects Models Julien Martinelli, Ibtissem Rebai, David W. Haas, Julie Bertrand Abstract High-dimensional genetic covariate selection in population pharmacokinetic (PK) models is challenging due to the cohort’s restricted size and high correlation among single-nucleotide polymorphisms (SNPs). We propose a fully Bayesian, single-stage framework that jointly infers nonlinear mixed effect model (NLMEM) parameters and SNP effect sizes, providing coherent posterior uncertainty and inclusion summaries within a single model fit. We compare five sparsity-inducing priors—Spike-and-Slab, Hierarchical Lasso, Regularized Horseshoe, R2–D2, and the ℓ 1 \ell_{1} -ball—calibrated through effect-size and sparsity targets. In simulations, all priors showed low false-discovery rates around 0 0 – 0.08 0.08 under the null, and recovered the causal signal under the alternative, with peak F 1 F_{1} scores around 0.8 0.8 – 0.85 0.85 under reasonable inclusion cutoffs. Spike-and-Slab was especially attractive because it provides analytical posterior inclusion probabilities directly, while among priors requiring tolerance-based proxy inclusion summaries, the ℓ 1 \ell_{1} -ball combined similarly strong recovery with the most stable behavior across tolerance values. On genetic and PK data from the ANRS 12154 study in 129 Cambodians living with HIV and receiving nevirapine, posterior predictive checks indicated adequate calibration and PK parameter inference remained stable across priors. While the dominant signal was robust across priors, additional candidate SNPs showed only partial agreement in ranking and more prior-sensitive effect-size estimates. These results support Bayesian variable selection within joint NLMEM as a principled approach for pharmacogenetic analyses when uncertainty quantification and regularization are central. 1 Introduction Inter-individual variability in drug exposure and response is a central concern in pharmacology and drug development. Patients receiving the same dose may exhibit markedly different concentration–time profiles and clinical outcomes, reflecting heterogeneity in physiological, environmental, and genetic factors. Pharmacogenetics (PGx) seeks to explain part of this variability by identifying genetic variants associated with pharmacokinetic (PK) or pharmacodynamic (PD) parameters, thereby improving mechanistic understanding of variability and informing individualized treatment strategies [ 1 ] . Nonlinear mixed-effects (NLME) models provide a principled framework to quantify population-level parameters, between-subject variability, and residual noise from PK/PD data while accommodating sparse and unbalanced designs. Embedding genetic covariates directly within an NLME model provides a principled alternative to two-stage procedures (e.g., association testing on empirical Bayes estimates), and has been shown to improve the calibration and power to detect pharmacogenetic covariates compared to approaches relying on observed concentrations or metrics derived from non-compartmental analyses. [ 2 ] . Yet, PGx covariate selection is often high-dimensional: many variants are evaluated in cohorts that are modest in size relative to the number of candidate SNPs. In practice, pharmacometric workflows have long relied on stepwise covariate model building and related frequentist strategies, which can be unstable and subject to selection-induced bias; uncertainty quantification can also become hard to interpret after selection. [ 3 ] Recent work has therefore explored penalized and stability-enhanced methods for NLME covariate selection [ 4 , 5 , 6 ] , but principled post-selection inference remains delicate in general [ 7 ] , and standard error estimation in NLME settings can be challenging under sparse designs or small cohorts. [ 8 , 9 ] Bayesian inference offers an appealing route to address these limitations by treating covariate effects, random effects, and observation noise jointly, and by propagating uncertainty coherently to downstream quantities and predictions. Bayesian population PK/PD modeling has a long history (e.g., via WinBUGS/PKBugs [ 10 ] ), but its routine use in NLME settings was historically constrained by the computational cost of sampling-based inference. This barrier has been progressively lowered by modern gradient-based algorithms—Hamiltonian Monte Carlo (HMC) and the No-U-Turn Sampler (NUTS) [ 11 , 12 ] —which exploit model geometry to explore high-dimensional posteriors efficiently, and by differentiable probabilistic programming frameworks that automate gradient computation and enable scalable implementations of HMC/NUTS [ 13 , 14 , 15 ] . A key benefit of the Bayesian paradigm is the ability to incorporate mechanistic or empirical prior information so that additional computation yields tangible gains in regularization, identifiability, and interpretability, as illustrated in dose-finding contexts, nonlinear joint models, and finite-sample uncertainty analyses. [ 16 , 17 , 18 ] In this work, we study Bayesian variable selection for pharmacogenetic covariates in NLME models and compare five complementary families of sparsity-inducing priors. Rather than committing to a single selection mechanism, we consider priors that span distinct design principles: mixture-based selection with analytical posterior inclusion probabilities (spike-and-slab), convex projection yielding exact zeros without discrete indicators ( \ell_{1} -ball), global–local shrinkage (hierarchical lasso and regularized horseshoe), and variance-explained parametrization (R2-D2) [ 19 , 20 , 21 , 22 , 23 ] . Each prior strongly concentrates most SNP effects near zero while retaining enough tail mass to accommodate occasional non-negligible effects—a key requirement for pharmacogenetic architectures dominated by a small number of variants. Recent pharmacometric work has also highlighted the practical appeal of continuous shrinkage priors, such as the regularized horseshoe, as a convenient alternative to stepwise covariate modeling. [ 24 ] Hereby, we first introduce the NLME model and the PGx parametrization used throughout, together with a prior calibration strategy reflecting expected effect sizes in PGx settings. We then present the five sparsity priors and the computational approach used for posterior inference. Next, we conduct a simulation study to assess calibration, selection accuracy, and robustness across priors and genetic architectures. Finally, we apply the framework to the 12154 ANRS study of nevirapine PGx in Cambodians living with Human immunodeficiency virus (HIV) type 1, where a well-established variant is modeled explicitly and the remaining SNP effects represent additional genetic contributions beyond this dominant determinant. We conclude with practical guidance on prior choice, diagnostics, and limitations. 2 Methods 2.1 Model and notations Let \mathbf{y}_{i} denote the vector of individual i=1,\dots,N observed concentrations at vector time \mathbf{t}_{i} , such that (\mathbf{t}_{i},\mathbf{y}_{i})=\{(t_{il},y_{il})\}_{l=1}^{n_{i}} , with n_{i} the number of sampling times t_{il} of patient i which we describe with the statistical model below: \displaystyle y_{il} \displaystyle=f\!\big(\boldsymbol{\phi}_{i};t_{il},D\big)+v_{il}, (1) \displaystyle\boldsymbol{\phi}_{i} \displaystyle=\exp(\boldsymbol{\mu}+\boldsymbol{\eta}_{i}), (2) where f(\cdot) is a mathematical function, corresponding to a PK compartmental model, nonlinear in its parameters \boldsymbol{\phi}_{i} notably composed of \boldsymbol{\eta}_{i}\sim\mathcal{N}(\mathbf{0},\boldsymbol{\Omega}) the individual random effects and with \mathbf{v}_{i}\sim\mathcal{N}(0,\sigma^{2}\mathbf{I}_{n_{i}}) the residual errors. Population-level parameters are \boldsymbol{\theta}=(\boldsymbol{\mu},\boldsymbol{\Omega},\sigma) : the fixed-effects vector \boldsymbol{\mu} , interindividual covariance \boldsymbol{\Omega} , and residual variance \sigma^{2} . Here, we consider a genetic effect on the h^{\text{th}} element of the vector \phi_{i} . All p single-nucleotide polymorphisms (SNPs) are coded in \{0,1,2\} according to the number of minor alleles and standardized to have mean zero and unit variance. Let \mathbf{X}\in\mathbb{R}^{N\times p} denote the resulting genotype matrix, with entry X_{i,j} for subject i and SNP j , and let \boldsymbol{\beta}=(\beta_{1},\ldots,\beta_{p})^{\top}\in\mathbb{R}^{p} denote the corresponding vector of SNP effects. Genetic effects are incorporated on the log-scale of the h^{\text{th}} PK parameter, so that for subject i \log\phi_{i,h}=\hat{\mu}_{h}+\sum_{j=1}^{p}X_{i,j}\beta_{j}+\eta_{ih}. (3) Posterior inference is performed using NUTS, an adaptive variant of Hamiltonian Monte Carlo [ 11 , 12 ] . The latter augments parameters q with momenta m and simulates Hamiltonian dynamics for the energy H(\mathbf{q},\mathbf{m})=-\log\pi(\mathbf{q})+\frac{1}{2}\mathbf{m}^{\top}\mathbf{M}^{-1}\mathbf{m}, (4) using a symplectic leapfrog integrator with a specific step size \epsilon and a mass matrix \mathbf{M} , followed by a Metropolis correction. This yields long-distance, gradient-informed proposals that